Heart Failure

Mesoblast Limited (NASDAQ: MESO) announced new analyses from the landmark DREAM-HF Phase 3 trial of rexlemestrocel-L in HFrEF patients with diabetes and/or ischemia who are at high risk of cardiovascular mortality, heart attacks, or strokes. In recent guidance to Mesoblast, FDA...

Mesoblast Limited (NASDAQ: MESO) presented new results from the landmark Phase 3 study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Data were shared at the American Heart Association annual Scientific Sessions. A single...

Bristol Myers Squibb & Co (NYSE: BMY) has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout.  Heart patients who received mavacamten in a cohort of the long-term MAVA-LTE study saw significant reductions in median levels of a...

Eli Lilly And Co (NYSE: LLY) and Boehringer Ingelheim have rolled out full results of EMPEROR-Preserved phase 3 trial of Jardiance (empagliflozin) for heart failure with preserved ejection fraction (HFpEF).  The data was delivered at the annual meeting of the European...